2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, (2R,4E)-
GW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).